Resproly
About:
Resproly is a respiratory system inhalation therapy and device developer.
Website: http://www.resproly.com/
Top Investors: BioVenture, Qianhai Fund of Funds, Fuho Capital, CAS Investment Management, Zhuhai Gree Financial Investment Management
Description:
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease.
Total Funding Amount:
$38M
Headquarters Location:
Zhuhai, Guangdong, China
Founded Date:
2018-01-01
Founders:
Yongqi Chen
Number of Employees:
101-250
Last Funding Date:
2022-04-30
IPO Status:
Private
Industries:
© 2025 bioDAO.ai